+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 1 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are investigating the optimal dose of tafenoquine for treating Plasmodium vivax malaria in Southeast Asia. This study compares the current recommended 300 mg dose of tafenoquine, which is less effective in this region, to a 50% higher dose. The trial also includes a comparison to high-dose primaquine in Indonesia, where primaquine is the standard care. The goal is to improve radical cure rates by reducing malaria recurrence. Participants will be randomly assigned to receive either the standard tafenoquine dose or a higher dose, both given as a single dose adjusted by weight bands. In Indonesia, a third group will receive high-dose primaquine daily for seven days. All participants will receive a schizonticidal agent such as chloroquine or artemether-lumefantrine alongside tafenoquine or primaquine. Drug administration will be directly observed to ensure adherence, and the treatments are given according to the national malaria guidelines. Participants will be followed daily until malaria parasites clear and then at several scheduled visits up to 4 months. These visits include blood tests, physical exams, and monitoring of adverse events and drug levels. If malaria recurs, treatment and follow-up restart as a new episode. The study measures include recurrence of infection by microscopy and molecular methods, adverse events, and drug levels over time. Data confidentiality and quality control procedures are in place, with a total participation duration of 4 months per episode.

Age: 2Years +All GendersPhase 4
6 locations